BG103966A - Лечение на диабет с тиазолидиндион и инхибитор наалфа глюкозидазата - Google Patents

Лечение на диабет с тиазолидиндион и инхибитор наалфа глюкозидазата Download PDF

Info

Publication number
BG103966A
BG103966A BG103966A BG10396699A BG103966A BG 103966 A BG103966 A BG 103966A BG 103966 A BG103966 A BG 103966A BG 10396699 A BG10396699 A BG 10396699A BG 103966 A BG103966 A BG 103966A
Authority
BG
Bulgaria
Prior art keywords
compound
alpha
administered
thiazolidine
dione
Prior art date
Application number
BG103966A
Other languages
Bulgarian (bg)
English (en)
Inventor
Stephen Smith
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG103966A publication Critical patent/BG103966A/bg

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
BG103966A 1997-06-18 1999-12-08 Лечение на диабет с тиазолидиндион и инхибитор наалфа глюкозидазата BG103966A (bg)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method
PCT/EP1998/003691 WO1998057635A1 (en) 1997-06-18 1998-06-15 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor

Publications (1)

Publication Number Publication Date
BG103966A true BG103966A (bg) 2000-07-31

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103966A BG103966A (bg) 1997-06-18 1999-12-08 Лечение на диабет с тиазолидиндион и инхибитор наалфа глюкозидазата

Country Status (24)

Country Link
EP (1) EP0975343A1 (no)
JP (1) JP2001523271A (no)
KR (1) KR20010013845A (no)
CN (1) CN1274282A (no)
AP (1) AP9901720A0 (no)
AR (2) AR013352A1 (no)
AU (1) AU8799998A (no)
BG (1) BG103966A (no)
BR (1) BR9810186A (no)
CA (1) CA2294134A1 (no)
CO (1) CO4940453A1 (no)
DZ (1) DZ2519A1 (no)
EA (1) EA200000040A1 (no)
IL (1) IL133138A0 (no)
MA (1) MA26510A1 (no)
NO (1) NO996270L (no)
NZ (1) NZ501345A (no)
OA (1) OA11631A (no)
PE (1) PE89199A1 (no)
PL (1) PL337577A1 (no)
SK (1) SK179499A3 (no)
TR (1) TR199903072T2 (no)
UY (1) UY25051A1 (no)
WO (1) WO1998057635A1 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064892A2 (en) 1999-04-23 2000-11-02 Smithkline Beecham P.L.C. Thiazolidinedione derivative and its use as antidiabetic
CA2442917C (en) 2001-04-04 2011-02-01 Ortho-Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
DE60233655D1 (de) 2001-04-04 2009-10-22 Ortho Mcneil Janssen Pharm R und retinoid x rezeptorenmodulatoren
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
CN101121004B (zh) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 含有胰岛素增敏剂和米格列醇的药物组合物
CN101584688B (zh) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物
CN101584705B (zh) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0601001B1 (en) * 1991-08-26 1997-04-16 PHARMACIA & UPJOHN COMPANY Liquid food product containing 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
EA200000040A1 (ru) 2000-08-28
CN1274282A (zh) 2000-11-22
JP2001523271A (ja) 2001-11-20
SK179499A3 (en) 2000-11-07
AR013352A1 (es) 2000-12-27
EP0975343A1 (en) 2000-02-02
PL337577A1 (en) 2000-08-28
CO4940453A1 (es) 2000-07-24
AR014881A1 (es) 2001-04-11
MA26510A1 (fr) 2004-12-20
NZ501345A (en) 2001-10-26
NO996270D0 (no) 1999-12-17
WO1998057635A1 (en) 1998-12-23
TR199903072T2 (xx) 2000-07-21
KR20010013845A (ko) 2001-02-26
BR9810186A (pt) 2000-08-08
AU8799998A (en) 1999-01-04
CA2294134A1 (en) 1998-12-23
AP9901720A0 (en) 1999-12-31
PE89199A1 (es) 1999-10-23
OA11631A (en) 2004-11-22
NO996270L (no) 1999-12-17
DZ2519A1 (fr) 2003-02-01
IL133138A0 (en) 2001-03-19
UY25051A1 (es) 2000-09-29

Similar Documents

Publication Publication Date Title
KR100666591B1 (ko) 티아졸리딘디온 및 메트포르민을 사용한 당뇨병의 치료
JP2005213273A (ja) チアゾリジンジオン、インスリン分泌促進薬およびジグアニドを用いる糖尿病の治療
JP2005247865A (ja) チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療
EA004800B1 (ru) Способ лечения диабета росиглитазоном и инсулином
BG103966A (bg) Лечение на диабет с тиазолидиндион и инхибитор наалфа глюкозидазата
KR20010013840A (ko) 티아졸리딘디온 및 술포닐우레아를 사용한 당뇨병의 치료
MXPA99012098A (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
CZ20001298A3 (cs) Léčivo pro léčení hyperglykémie a farmaceutický prostředek s obsahem sensitizéru inzulinu
US20020123514A1 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor
MXPA99012078A (en) Treatment of diabetes with thiazolidinedione and metformin
MXPA99012091A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
MXPA00000633A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide
BG104404A (bg) Използване на тиазолидиндиони за лечение на хипергликемия
MXPA00003634A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
MXPA00000655A (en) Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
CZ2000172A3 (cs) Léčivo pro léčbu diabetes mellitus a stavů s diabetes mellitus spojených a farmaceutický prostředek
UA68352C2 (en) Method for treatment of diabetes mellitus with thiazolidin and metformin
CZ2000174A3 (cs) Farmaceutický prostředek proti diabetů mellitus a stavům s ním spojeným
MXPA00000631A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
CZ9904580A3 (cs) Léčivo pro léčbu diabetes mellitus a stavů spojených s diabetes mellitus
MXPA00003633A (en) Use of thiazolidinediones for the treatment of hyperglycaemia